News | December 30, 2025
Harbour BioMed teams up with Lannacheng to advance next-generation cancer therapies
Harbour BioMed brings advanced antibody discovery platforms to the table
Harbour BioMed brings advanced antibody discovery platforms to the table
The Phase 1 study will evaluate the safety, tolerability, and pharmacokinetics (PK) of ENV-6946 in healthy volunteers
Under the 2023 collaboration agreement, Assembly Bio will receive $35 million for Gilead’s exercise of the HSV program option
The randomized, double-blind, placebo-controlled single ascending dose (SAD) study evaluated safety, tolerability, pharmacokinetics, and target engagement in 46 healthy participants
Adverse events were similar to placebo, and no AP-101-induced antibody responses were detected
MRI is particularly valuable in pediatric care due to its non-invasive nature
AEF0217 is a first-in-class CB1 receptor signaling-specific inhibitor
Health Canada’s approval was based on a comprehensive evaluation of analytical, nonclinical, and clinical data
The company also revealed that MK-2214 has received Fast Track Designation from the U.S. Food and Drug Administration
Gobivaz is authorised for adults with rheumatoid arthritis (in combination with methotrexate), psoriatic arthritis (with or without methotrexate), axial spondyloarthritis, and ulcerative colitis
Subscribe To Our Newsletter & Stay Updated
_256_275.jpeg)
